Skip to content

Atypical Hemolytic Uremic Syndrome With Mcp Cd46 Anomaly C2752040

Published: July 22, 2026Updated: August 20, 2026

A genetic form of aHUS involving mutations in the MCP/CD46 complement regulator. Can affect both children and adults. Some patients may improve without treatment. Complement inhibitors are used when needed.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q63.9
ICD-11
LA00.0
Body system
renal
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Microangiopathic hemolytic anemia

!

Hypertension

!

Confusion

Changes in urination or swelling

(renal)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Hematuria

(renal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Complement C5 Inhibitor Therapy

Monoclonal antibodies targeting complement C5 to prevent complement-mediated endothelial damage and thrombotic microangiopathy. This therapy addresses the underlying pathophysiology of MCP/CD46 deficiency in aHUS.

medication
2

Renal disease management

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Plasma Exchange

Therapeutic plasma exchange removes autoantibodies and replaces deficient complement regulatory proteins. Used as adjunctive therapy or bridge treatment while awaiting complement inhibitor effect.

procedure

Additional treatment options

Laboratory and Renal Monitoring

Regular monitoring of hematologic parameters including LDH, haptoglobin, schistocytes, creatinine, and urine protein to detect disease recurrence and assess treatment response.

monitoring

Antihypertensive Management

Blood pressure control with agents such as ACE inhibitors or ARBs to manage hypertension secondary to renal involvement and reduce cardiovascular risk in this prothrombotic condition.

medication

Renal-Protective Diet

Dietary modifications including sodium restriction, controlled protein intake, and management of potassium and phosphorus levels to support kidney function and reduce cardiovascular burden.

dietary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Atypical Hemolytic Uremic Syndrome With Mcp Cd46 Anomaly C2752040?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017.

guideline2017
2

Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011.

review2011
3

Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2015.

clinical_trial2015
4

Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009.

review2009

Medication Comparisons

Compare medications used to treat Atypical Hemolytic Uremic Syndrome With Mcp Cd46 Anomaly C2752040. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy